Bioprojet's orphan drug for EDS enters Phase III trials
This article was originally published in Scrip
Executive Summary
The privately owned French biotech firm Bioprojet says that its new compound for excessive daytime sleepiness (EDS), pitolisant, has shown good results in several European Phase II trials and has now begun Phase III development.